SEC 13F Intelligence

Ghost Tree Capital, LLC / TCE2

Ghost Tree Capital, LLC’s Celldex Therapeutics Inc New Position

Does Ghost Tree Capital, LLC own Celldex Therapeutics Inc New (TCE2)? Not currently — the last reported position was 300.0K shares worth $10M in Q1 2022; the fund’s latest 13F (Q3 2024) no longer reports it.

Position Value
$10M
Q1 2022
Shares
300.0K
% of Portfolio
+2.22%
Quarters Held
5
position exited

Position History TCE2

Reported value by quarter
Q1 ’21: $5MQ1 ’21Q2 ’21: $10MQ2 ’21Q3 ’21: $14MQ3 ’21Q4 ’21: $14MQ4 ’21Q1 ’22: $10MQ1 ’22filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2022300.0K$10M+2.22%
Q4 2021350.0K$14M+4.85%
Q3 2021255.0K$14M+4.03%
Q2 2021285.0K$10M+2.62%
Q1 2021250.0K$5M+1.21%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Ghost Tree Capital, LLC’s full portfolio or all institutional holders of TCE2.